Skip to content
10-Q

Quarterly Report

Urovant Sciences Ltd.

0001564590-20-049692

← back to feed
Filed
Nov 2, 2020 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2020 · Nov 2, 2020 31.66M sh
Operating Cash Flow Q2 2020 · Sep 30, 2020 −$63.44M
Operating Cash Flow Q2 2020 · Sep 30, 2019 −$46.97M
Long Term Debt Q2 2020 · Sep 30, 2020 $171.28M
Cash And Equivalents Q2 2020 · Sep 30, 2020 $74.4M
Cash And Equivalents Q2 2020 · Mar 31, 2020 $51.41M
Stockholders Equity Q2 2020 · Sep 30, 2020 −$113.05M
Stockholders Equity Q2 2020 · Jun 30, 2020 −$84.94M
Stockholders Equity Q2 2020 · Mar 31, 2020 −$58.01M
Stockholders Equity Q2 2020 · Sep 30, 2019 $23.76M
Stockholders Equity Q2 2020 · Jun 30, 2019 $47.72M
Stockholders Equity Q2 2020 · Mar 31, 2019 $74.77M
Current Liabilities Q2 2020 · Sep 30, 2020 $28.84M
Current Liabilities Q2 2020 · Mar 31, 2020 $30.93M
Total Liabilities Q2 2020 · Sep 30, 2020 $204.51M
Total Liabilities Q2 2020 · Mar 31, 2020 $121.3M
Current Assets Q2 2020 · Sep 30, 2020 $83.85M
Current Assets Q2 2020 · Mar 31, 2020 $58.32M
Total Assets Q2 2020 · Sep 30, 2020 $91.46M
Total Assets Q2 2020 · Mar 31, 2020 $63.3M
Sga Expense Q2 2020 · Sep 30, 2020 $18.93M
Sga Expense Q2 2020 · Sep 30, 2020 $31.42M
Sga Expense Q2 2020 · Sep 30, 2019 $7.44M
Sga Expense Q2 2020 · Sep 30, 2019 $12.9M
Rd Expense Q2 2020 · Sep 30, 2020 $14.54M
Rd Expense Q2 2020 · Sep 30, 2020 $30.89M
Rd Expense Q2 2020 · Sep 30, 2019 $17.8M
Rd Expense Q2 2020 · Sep 30, 2019 $39.81M
Net Income Q2 2020 · Sep 30, 2020 −$35.16M
Net Income Q2 2020 · Sep 30, 2020 −$65.65M
Net Income Q2 2020 · Jun 30, 2020 −$30.49M
Net Income Q2 2020 · Sep 30, 2019 −$25.74M
Net Income Q2 2020 · Sep 30, 2019 −$54.23M
Net Income Q2 2020 · Jun 30, 2019 −$28.49M